Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Cytokine & Growth Factor Reviews,
Год журнала:
2024,
Номер
79, С. 29 - 38
Опубликована: Авг. 24, 2024
Язык: Английский
Role of Radiomics-based Multiomics Panel in the Microenvironment and Prognosis of Hepatocellular Carcinoma
Ziqian Wu,
Siyu Ouyang,
Jidong Gao
и другие.
Academic Radiology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma
Biomarker Research,
Год журнала:
2025,
Номер
13(1)
Опубликована: Март 4, 2025
Hepatocellular
carcinoma
(HCC)
can
be
classified
into
several
subtypes
based
on
molecular
traits,
aiding
in
prognostic
stratification.
The
subtype
with
a
poor
prognosis
is
often
associated
stem/progenitor
features.
This
study
focused
identifying
circulating
biomarkers
for
aggressive
HCC.
We
searched
secretory
proteins
whose
expression
was
positively
the
markers
KRT19,
EPCAM,
and
PROM1
2
independent
HCC
cohorts.
Serum
folate
receptor
1
(FOLR1)
levels
were
measured
238
chronic
liver
disease
247
patients,
evaluating
their
diagnostic
capabilities.
FOLR1
identified
as
protein
that
correlated
all
3
both
discovery
validation
Higher
detected
tumor
than
nontumor
tissues
subtypes,
activation
of
p53,
DNA
repair,
Myc,
E2F,
PI3K/AKT/mTOR
pathways.
tumoral
patients
significantly
elevated
compared
those
hepatitis
or
nonliver
disease.
demonstrated
performance
comparable
to
alpha-fetoprotein
(AFP),
combination
increased
accuracy.
Elevated
serum
regardless
treatment,
especially
early-stage
multivariate
analysis
revealed
level
Gender,
Age,
AFP-L3,
AFP,
Des-gamma-carboxy
prothrombin
(GALAD)
score
predictors
further
stratifying
prognosis.
stemness-associated
biomarker
HCC,
serving
marker
indicator
Язык: Английский
The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma
Biomarker Research,
Год журнала:
2025,
Номер
13(1)
Опубликована: Апрель 12, 2025
Hepatocellular
carcinoma
(HCC)
remains
one
of
the
most
prevalent
and
deadliest
cancers.
With
approval
multiple
first-
second-line
agents,
especially
combination
therapies
based
on
immune
checkpoint
inhibitor
(ICI)
regimens,
landscape
systemic
therapy
for
advanced
HCC
(aHCC)
is
more
diverse
than
ever
before.
The
efficacy
current
shows
great
heterogeneity
in
patients
with
aHCC,
thereby
identifying
biomarkers
response
prediction
patient
stratification
has
become
an
urgent
need.
main
hepatocellular
are
derived
from
peripheral
blood,
tissues,
imaging.
Currently,
understanding
clinical
to
indicates
unequivocally
that
a
single
biomarker
cannot
be
used
identify
who
likely
benefit
these
treatments.
In
this
review,
we
provide
integrated
recent
development
molecular
targeted
ICIs-based
therapies,
focusing
role
clinically
applicable
predictive
biomarkers.
Additionally,
further
highlight
latest
advancements
biomarker-driven
including
treatments,
adoptive
cell
bispecific
antibodies.
Язык: Английский
High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy of Paired Clinical Liver Tissue Samples from Hepatocellular Cancer and Surrounding Region
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(16), С. 8924 - 8924
Опубликована: Авг. 16, 2024
The
global
burden
of
liver
cancer
is
increasing.
Timely
diagnosis
important
for
optimising
the
limited
available
treatment
options.
Understanding
metabolic
consequences
hepatocellular
carcinoma
(HCC)
may
lead
to
more
effective
We
aimed
document
metabolite
differences
between
HCC
and
matched
surrounding
tissues
varying
aetiology,
obtained
at
time
resection,
interpret
changes
with
clinical
findings.
High-resolution
magic
angle
spinning
nuclear
magnetic
resonance
(HRMAS-NMR)
spectroscopy
analyses
N
=
10
paired
non-tumour
tissue
samples
were
undertaken.
There
marked
HRMAS-NMR
in
lipid
levels
compared
subtle
low-molecular-weight
metabolites,
particularly
when
adjusting
patient-specific
variability.
Differences
lipid-CH3,
lipid-CH2,
formate,
acetate
particular
interest.
obvious
content
highlight
intricate
interplay
adaptations
cell
survival
complex
microenvironment
cancer.
formate
might
relate
bacterial
metabolites.
Therefore,
documentation
metabolites
according
histology
findings
patients
interest
personalised
medicine
approaches
tailoring
targeted
strategies.
Язык: Английский
Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review
Diagnostics,
Год журнала:
2024,
Номер
14(18), С. 2054 - 2054
Опубликована: Сен. 16, 2024
Hepatocellular
carcinoma
(HCC),
the
most
common
primary
liver
malignancy
and
sixth
cancer
globally,
remains
fatal
for
many
patients
with
inappropriate
responses
to
treatment.
Recent
advancements
in
immunotherapy
have
transformed
treatment
landscape
advanced
HCC.
However,
variability
patient
highlights
need
biomarkers
that
can
predict
outcomes.
This
manuscript
comprehensively
reviews
evolving
role
of
efficacy,
spanning
from
blood-derived
indicators—alpha-fetoprotein,
inflammatory
markers,
cytokines,
circulating
tumor
cells,
their
DNA—to
tissue-derived
indicators—programmed
cell
death
ligand
1
expression,
mutational
burden,
microsatellite
instability,
tumor-infiltrating
lymphocytes.
The
current
body
evidence
suggests
these
hold
promise
improving
selection
predicting
Each
biomarker
offers
unique
insights
into
disease
biology
immune
HCC,
potentially
enhancing
precision
strategies.
challenges
such
as
methodological
variability,
high
costs,
inconsistent
findings,
large-scale
validation
well-powered
two-arm
trial
studies
persist,
making
them
currently
unsuitable
integration
standard
care.
Addressing
through
standardized
techniques
implementation
further
will
be
critical
future
incorporation
clinical
practice
Язык: Английский
“Single‐cell multimodal chromatin profiles revealing epigenetic regulations of cells in hepatocellular carcinoma”
Clinical and Translational Discovery,
Год журнала:
2024,
Номер
4(5)
Опубликована: Окт. 1, 2024
Abstract
Hepatocellular
carcinoma
(HCC),
with
its
increasing
prevalence
globally,
is
emerging
as
a
major
health
challenge.
cells
exhibit
both
significant
homogeneity
and
heterogeneity,
governed
by
complex
epigenomic
regulations.
Recently,
numerous
single‐cell
unimodal
techniques
have
been
used
to
study
HCC
at
various
levelswhich
already
revealed
interplay
genomic,
transcriptomic,
spatial
levels.
However,
the
use
of
multimodal
combining
different
layers
in
remains
quite
limited,
necessitating
further
studies
focusing
on
these
methods
uncover
novel
markers,
mechanisms
epigenetic
In
this
commentary,
we
highlight
how
integrating
approaches
modifications
can
provide
new
insights
into
foster
future
therapeutic
advancements.
Язык: Английский